- Home
- LPTX vs KLXE Comparison
LPTX vs KLXE Comparison
Compare LPTX & KLXE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- KLXE
- Stock Information
- Founded
- LPTX 2011
- KLXE 2018
- Country
- LPTX United States
- KLXE United States
- Employees
- LPTX N/A
- KLXE 1919
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- KLXE Oilfield Services/Equipment
- Sector
- LPTX Health Care
- KLXE Energy
- Exchange
- LPTX Nasdaq
- KLXE Nasdaq
- Market Cap
- LPTX 99.5M
- KLXE 79.4M
- IPO Year
- LPTX N/A
- KLXE N/A
- Fundamental
- Price
- LPTX $3.05
- KLXE $5.16
- Analyst Decision
- LPTX Strong Buy
- KLXE Hold
- Analyst Count
- LPTX 3
- KLXE 1
- Target Price
- LPTX $7.50
- KLXE $4.50
- AVG Volume (30 Days)
- LPTX 437.3K
- KLXE 104.4K
- Earning Date
- LPTX 11-13-2024
- KLXE 10-31-2024
- Dividend Yield
- LPTX N/A
- KLXE N/A
- EPS Growth
- LPTX N/A
- KLXE N/A
- EPS
- LPTX N/A
- KLXE N/A
- Revenue
- LPTX N/A
- KLXE $738,000,000.00
- Revenue This Year
- LPTX N/A
- KLXE N/A
- Revenue Next Year
- LPTX N/A
- KLXE $4.79
- P/E Ratio
- LPTX N/A
- KLXE N/A
- Revenue Growth
- LPTX N/A
- KLXE N/A
- 52 Week Low
- LPTX $1.68
- KLXE $4.18
- 52 Week High
- LPTX $5.00
- KLXE $12.13
- Technical
- Relative Strength Index (RSI)
- LPTX 51.79
- KLXE 39.30
- Support Level
- LPTX $2.87
- KLXE $4.90
- Resistance Level
- LPTX $3.12
- KLXE $5.34
- Average True Range (ATR)
- LPTX 0.28
- KLXE 0.37
- MACD
- LPTX 0.02
- KLXE -0.13
- Stochastic Oscillator
- LPTX 49.42
- KLXE 22.45
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About KLXE KLX Energy Services Holdings Inc.
KLX Energy Services Holdings Inc is a provider of completion, intervention and production services and products to the onshore oil and gas producing regions of the United States. It serves the companies engaged in the exploration and development of onshore conventional and unconventional oil and natural gas reserves. Its products and services offerings include surface facilities and equipment, pressure control services, wireline services, fishing services, and engineered products. The company's segments include Southwest; Rocky Mountains and Northeast/Mid-Con region. It derives maximum revenue from Northeast/Mid-Con region.